ArticleDiagnostic pathology2009
CD10 expression in urothelial carcinoma of the bladder.
Article in Diagnostic pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Evaluation of CD10 Expression in Endometrial Carcinoma: A Systematic Review.Iranian journal of pathology · 2026Review
- Identification of potential biomarkers for lung cancer using integrated bioinformatics and machine learning approaches.PloS one · 2025Article
- Clinicopathological patterns of bladder carcinoma over 1 year: experience from University Hospital of Nepal.International urology and nephrology · 2021Article
- Assessing CD 10 Expression Level and Its Prognostic Impact in Egyptian Patients with Urothelial Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Spinal Versus Intracranial Meningioma: Aberrant Expression of CD10 and Inhibin with Relation to Clinicopathological Features and Prognosis.Pathology oncology research : POR · 2020Article
- The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients.Scientific reports · 2019Article
- Role of CD10 Marker in Differentiating Malignant Thyroid Neoplasms from Benign Thyroid Lesions (Immunohistochemical & Histopathological Study).Open access Macedonian journal of medical sciences · 2018Article
- Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2.Oncotarget · 2016Article
- Correlation of Wnt5a expression with histopathological grade/stage in urothelial carcinoma of the bladder.Diagnostic pathology · 2013Article
- CD10 and CA19.9 immunohistochemical expression in transitional cell carcinoma of the urinary bladder.Urology annals · 2013Article
- A step towards refining prognostication in individual patients with bladder cancer.Urology annals · 2013Article
- Immunohistochemical expression of Fas ligand (FasL) and neprilysin (neutral endopeptidase/CD10) in keratoconus.International ophthalmology · 2013Article
- CD10 Is Again Expressed at a Certain Stage during the Neoplastic Process of Bladder Transitional Cell Carcinomas.Cancer research and treatment · 2012Article
- Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer.Diagnostic pathology · 2012Article
- Immunohistochemical Analysis of p53, CD10 and Ki67 Expression as Prognostic Biomarkers in Urinary Bladder Carcinomas Correlating with Age, Histomorphology, Grade and Stage: An Institutional Study of One and Half Year.Journal of microscopy and ultrastructureArticle
- CD10 expression in urinary bladder urothelial carcinoma is associated with high-tumor grade and stage.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD10 antigen is a 100-kDa-cell surface zinc metalloendopeptidase and it is expressed in a variety of normal and neoplastic lymphoid and nonlymphoid tissues. The aim of this study was to evaluate CD10 expression in urothelial carcinoma of the urinary bladder and to determine the correlation between immunohistochemical (IHC) CD10 expression and histopathologic parameters including grade and stage.
methods371 cases of urothelial bladder carcinomas, all from transurethral resections, were included in this study. Hematoxylin-eosin (HE) stained sections from each case were reevaluated histopathologically according to WHO 2004 grading system. The TNM system was used for pathologic staging. Selected slides were also studied by IHC and a semiquantitative scoring for CD10 expression based on the percentage of positive cells was performed.
results157 cases (42.3%) showed immunostaining while 214 cases (57.7%) were negative for CD10. 1+ staining was seen in 65 CD10 positive cases (41.4%), and 2+ in 92 cases (58.6%). Overall CD10 expression as well as 2+ immunostaining was significantly correlated with high histologic grade. Overall CD10 expression was also significantly higher in invasive pT1 and pT2-3 tumors compared to noninvasive pTa tumors. pT1 and pT2-3 tumors were also significantly correlated with 2+ immunostaining.
conclusionTo date, only a few comparative IHC studies have assessed CD10 expression in urothelial carcinoma of the urinary bladder and this study represents the largest series. Our findings indicate that CD10 expression is strongly correlated with high tumor grade and stage in urothelial carcinoma of the bladder, and that CD10 may be associated with tumor progression in bladder cancer pathogenesis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.